Patell Slides - US-Asia Technology Management Center

Transcription

Patell Slides - US-Asia Technology Management Center
Doing Business With Your
Technology in Asia
High-Growth Asia Markets - Panel 2
Emerging Biotech Markets in Asia
Dr. Villoo Morawala Patell
Founder & CEO, Avesthagen
Avesthagen: The Food-Pharma Convergence Platform
Nutrition
for health
Seed for food
Foods
Health Foods
Plant for
medicine
Bio-therapeutics
Supplements
Agenda
¾ Biotechnology in Asia
¾ Funding to Milestones – Conventional vs. Avesthagen Experience
¾ Global Model for Indian Biotechnology
¾ Balancing R&D Services with IP Development
Biotechnology in Asia
• Asia is the second largest biotech market in the world with
an anticipated revenue of $100 by 2005
• A snapshot of Asia Pacific countries spending to build
their biotech industry :
Korea plans to spend $10.8B
Singapore has set aside $2B
over the next 5 years
towards biotechnology industry.
DBT in India has set up
$21 million venture fund.
Japan wants to create $ 217 billion
biotechnology industry to employ
Taiwan is promoting BT as the
In China, in 10 years 50% of nation
80,000 people in 1000 biotech
next major growth sector& creating biotech
field are expected to be planted
firms by 2010.
Manufacturing zones in each
with biotechnology crop.
of 5 industrial parks.
Asia/Pacific (excluding Japan) Bio-IT Percentage
Split by Sub-Region (2002)
Source: RIS, India
Funding to Milestones - ‘Venture Capital Model’
Idea is
Feasible
Risk (ß)
Knowledge
KnowledgeAcquisition
Acquisition
&&Concept
Investigation
Concept Investigation
P(success) = 30%
Reqd IRR = 100%
Company / IP Valuation
Capital
Seed
Funding
Friends and Family
Funding to Milestones - ‘Venture Capital Model’
Idea is
Feasible
Technology
Woks
Risk (ß)
Basic
BasicDesign
Design&&
Prototype
PrototypeBuilding
Building
P(success) = 30%
Reqd IRR = 100%
Patent
PatentApplication
Application
P(success) = 40%
Reqd IRR = 70%
Company / IP Valuation
Capital
Seed
Funding
R&D
Capital
Venture Capital
Funding to Milestones - ‘Venture Capital Model’
Idea is
Feasible
Technology
Works
A Customer
Buys
Market
MarketEntry
Entry
P(success) = 50%
Reqd IRR = 50%
Risk (ß)
Patent
PatentGranted
Granted
Company / IP Valuation
P(success) = 30%
Reqd IRR = 100%
P(success) = 40%
Reqd IRR = 70%
Capital
Seed
Funding
R&D
Capital
Go-to-Market
Captial
Domain specific Venture Capital
Funding to Milestones - ‘Venture Capital Model’
Idea is
Feasible
Technology
Works
A Customer
Buys
P(success) = 80%
Req’d IRR = 30%
Manufacturing
Manufacturing
Ramp-up
Ramp-up
P(success) = 50%
Reqd IRR = 50%
Company / IP Valuation
Risk (ß)
P(success) = 30%
Reqd IRR = 100%
P(success) = 40%
Reqd IRR = 70%
IP
IPOut-licensing
Out-licensing
Capital
Seed
Funding
R&D
Capital
Go-to-Market
Captial
Expansion
Captial
IPO
Funding to Milestones – ‘Avesthagen Experience’
Idea is
Feasible
Technology
Works
A Customer
Buys
Interim Funding Round
($720K @ 24% interest)
Technology Grants ($1.08
million in loans)
Risk (ß)
Company/ IP Valuation
Absence of
Biotech Domain
Investors
Seed
Funding
$300K
Series A
Funding
$1.8 million
Go-to-Market
Captial
Capital
Expansion
Captial
Flat IPO
Market!
Global Model for Biotechnology in India
Avesthagen SA
Avesthagen SA
Research
based in Europe to
ResearchOutsourcing
Outsourcingplatform
platform
based
in Europe to
Avesthagen
Inc.
based
ininBangalore
with
market services and
Avesthagen Inc.
based
Bangalore
with
market services and
based
competencies
in
genomics,
appropriate technologies to
basedininSan
SanDiego
Diegowill
willdevelop
develop
competencies in genomics,
appropriate technologies to
and
proteomics,
potential partners
andmarket
marketnutraceuticals
nutraceuticalsderived
derived
proteomics,bioinformatics
bioinformatics
potential partners
from
medicinal
plants
with
focus
and
HT
cell
assay
AQUAS
from medicinal plants with focus
and HT cell assaysystems
systems
AQUAS
on
Diabetes
and
Obesity
based
in
Hyderabad
in
partnership
on Diabetes and Obesity
based in Hyderabad in partnership
with
withICRISAT,
ICRISAT,has
has
competencies
competenciesininbiological
biological
Quality
Qualitytesting
testingservices
services
Our Objectives
Our Solution
Leverage India’s low cost-structure and
access to skilled scientists as a key
competitive advantage
Establish an integrated biotechnology
platform as a “Research Outsourcing” Station
Enable the valuation of IP and therefore
the company at global standards
Establish subsidiaries and Joint Ventures with
partners in the US and Europe enabled
through project-based funding
Establish close access to markets and
clients in the US and EU
The subsidiary / JV shares the IP on products
and technologies and markets them.
Un-fettered access to the capital
markets in the US and EU
Research is outsourced to the “Research
Outsourcing” Station in Bangalore
Research Process Outsourcing™ - RPO™
Transformation led by
“brainware” leverage
¾ Limited access to venture capital means that R&D services and IP
development must balance each other for the company to be sustainable.
¾ RPO™ is characterized by a shared “objectives” based relationship,
¾ Avesthagen participates in the firms R&D and IP development process,
¾ Avesthagen helps the firm to broaden competency and manage R&D cost
through leveraging the India Advantage!
Revenue Model using RPO™
High Risk / Large
invested capital
Cash out through highmargin products
Out-licensing / Royalties
Co-development of IP based on
existing portfolio and market
opportunities
Strategic investment led
R&D
RPO™ - fee for service
Low Risk / Small
invested capital
Manage exposure
to risk through
shared IP
Partner led IP development
Build competency and partnerships
Our Value Proposition
RPO™ Process Flow
R-Audit
R-Audit Services
Services
Process
Process // Solution
Solution
Study
Study
Outsourcing
Outsourcing Services
Services
Project
Project Handling
Handling
Integration
Integration Services
Services
Integration
Integration
Support
Support
••Report
Report Generation
Generation
••Study
Study segments
segments to
to
outsource
outsource
••Protocol
Protocol development
development
••Cost
Cost and
and quality
quality benefit
benefit
••Technology
Technology Transfer
Transfer
••Develop
Develop benchmarks
benchmarks
••Consumable
Consumable sourcing
sourcing
••Data
Data integration
integration
and
and curation
curation
••Process
Process and
and Cost
Cost
optimization
optimization
Competencies at Avesthagen that enable the RPO™ Model
Functional Genomics
¾Customized cDNA libraries
¾Whole Genome Sequencing
¾Genotyping and DNA fingerprinting
¾MAS, Marker development
Population Genomics
¾Disease databases
¾Drug target discovery
¾Screening for drug response
Validation of in-silico systems
¾Gene Annotation
¾Protein-Protein interaction
¾Data Curation and functional classification
Biotherapeutics
¾Proteome profiling - 2D-GE, Comparative gel
analysis and PMF
¾Cloning, Expression, Purification, Prep-HPLC for
lab scale production of bioactive proteins
¾Pharming – Transformation for expression of
therapeutics in plants
¾ Development and validation of protocols
Current Partners – RPO™ Works!
CSIR
Stazione
Zoologica
Napoli
ICRISAT
Current Product Development Programs at Avesthagen
¾ Discovery of nutritional compounds that are effective against diabetes and obesity from
Indian medicinal plants and formulations described in traditional medicine. The product
development effort is supported by the International Bank for Reconstruction and
Development (IBRD) program.
¾ Genetic Manipulation of Helianthus annus L. for production of Docosahexaenoic acid
(DHA). In partnership CSIR labs in Goa (NIO) and Jammu (RRL) under the NMITLI
program.
¾ Identification and Characterization of Aroma Genes from Basmati Rice.
Nutraceutical Discovery Program
Disease
selection
Literature &
Data collection
Targeted screening of
Formulations for
Nutritional Compounds
Tribal herbal
medicine, Ayurveda,
Unani, Siddha
Fractionation
Relevant
Medicinal Plants
Target and Etiology
identification
In-vitro and Invivo models
Enzymes/Signal Transducers/
Regulatory Proteins/Target
and Non-Target SNP’S
Multiple extractions
Nutraceutical Leads
Toxicity
Marketed
Products
Clinical Validation
Validation of
Extraction by
Bioassay
Conclusion
¾ Biotech companies in the region need to have the best
breed of technology, product & services and IPR strategy.
www.CartoonStock.com
Thank You!